| Imperial Healthcare Center | |
| 11926 La Mirada Blvd, La Mirada, California 90638 | |
| (562) 943-7156 | |
| Name | Imperial Healthcare Center |
|---|---|
| Location | 11926 La Mirada Blvd, La Mirada, California |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 99 |
| Occupancy Rate | 92.02% |
| Medicare ID (CCN) | 056115 |
| Legal Business Name | La Mirada Healthcare, Llc |
| Ownership Type | For Profit - Limited Liability Company |
| NPI Number | 1043251077 |
| Organization Name | LIFE CARE CENTERS OF AMERICA, INC. |
| Doing Business As | IMPERIAL CONVALESCENT HOSPITAL |
| Address | 11926 La Mirada Blvd, La Mirada, CA 90638 |
| Phone Number | 562-943-7156 |
News Archive
Gen-Probe announced today that Health Canada has granted the Company a medical device license for the PROGENSA(R) PCA3 assay, a new molecular urine test that helps determine the need for repeat biopsies in men suspected of having prostate cancer.
Boston Medical Center has been chosen to lead an investigation aimed at developing novel approaches to prevent tuberculosis. Jerrold J. Ellner, MD, chief of the section of infectious diseases at BMC and professor of medicine at the Boston University School of Medicine, a renowned expert in the field, will serve as principal investigator on the five-year, $3 million grant funded by the National Institutes of Health.
Osteotech, Inc. ( NASDAQ:OSTE ) , a leader in the emerging field of biologic solutions for regenerative medicine, announced today that the United States Patent and Trademark Office has confirmed the validity of its U.S. Patent No. 5,676,146.
Aperio Technologies, Inc., (Aperio), a global leader in digital pathology for the healthcare and life sciences industry, announced today that the United States Patent and Trademark Office has issued the company patent No. 7,457,446 entitled "Fully Automatic Rapid Microscope Slide Scanner."
The aldosterone antagonist eplerenone significantly reduced the development of new onset atrial fibrillation and flutter in patients with class 2 heart failure, concludes a sub-analysis of the EMPHASIS-HF trial, presented at the Heart Failure Congress 2011, organized by the Heart Failure Association of the European Society of Cardiology.
› Verified 5 days ago
| NPI Number | 1194921882 |
| Address | 11926 La Mirada Blvd, La Mirada, CA 90638 |
| Phone Number | 562-943-7156 |
News Archive
Gen-Probe announced today that Health Canada has granted the Company a medical device license for the PROGENSA(R) PCA3 assay, a new molecular urine test that helps determine the need for repeat biopsies in men suspected of having prostate cancer.
Boston Medical Center has been chosen to lead an investigation aimed at developing novel approaches to prevent tuberculosis. Jerrold J. Ellner, MD, chief of the section of infectious diseases at BMC and professor of medicine at the Boston University School of Medicine, a renowned expert in the field, will serve as principal investigator on the five-year, $3 million grant funded by the National Institutes of Health.
Osteotech, Inc. ( NASDAQ:OSTE ) , a leader in the emerging field of biologic solutions for regenerative medicine, announced today that the United States Patent and Trademark Office has confirmed the validity of its U.S. Patent No. 5,676,146.
Aperio Technologies, Inc., (Aperio), a global leader in digital pathology for the healthcare and life sciences industry, announced today that the United States Patent and Trademark Office has issued the company patent No. 7,457,446 entitled "Fully Automatic Rapid Microscope Slide Scanner."
The aldosterone antagonist eplerenone significantly reduced the development of new onset atrial fibrillation and flutter in patients with class 2 heart failure, concludes a sub-analysis of the EMPHASIS-HF trial, presented at the Heart Failure Congress 2011, organized by the Heart Failure Association of the European Society of Cardiology.
› Verified 5 days ago
| NPI Number | 1255742904 |
| Organization Name | LA MIRADA HEALTHCARE, LLC |
| Address | 11926 La Mirada Blvd, La Mirada, CA 90638 |
| Phone Number | 818-985-6600 |
News Archive
Gen-Probe announced today that Health Canada has granted the Company a medical device license for the PROGENSA(R) PCA3 assay, a new molecular urine test that helps determine the need for repeat biopsies in men suspected of having prostate cancer.
Boston Medical Center has been chosen to lead an investigation aimed at developing novel approaches to prevent tuberculosis. Jerrold J. Ellner, MD, chief of the section of infectious diseases at BMC and professor of medicine at the Boston University School of Medicine, a renowned expert in the field, will serve as principal investigator on the five-year, $3 million grant funded by the National Institutes of Health.
Osteotech, Inc. ( NASDAQ:OSTE ) , a leader in the emerging field of biologic solutions for regenerative medicine, announced today that the United States Patent and Trademark Office has confirmed the validity of its U.S. Patent No. 5,676,146.
Aperio Technologies, Inc., (Aperio), a global leader in digital pathology for the healthcare and life sciences industry, announced today that the United States Patent and Trademark Office has issued the company patent No. 7,457,446 entitled "Fully Automatic Rapid Microscope Slide Scanner."
The aldosterone antagonist eplerenone significantly reduced the development of new onset atrial fibrillation and flutter in patients with class 2 heart failure, concludes a sub-analysis of the EMPHASIS-HF trial, presented at the Heart Failure Congress 2011, organized by the Heart Failure Association of the European Society of Cardiology.
› Verified 5 days ago
| NPI Number | 1740684380 |
| Organization Name | LA MIRADA HEALTCHARE LLC |
| Address | 11926 La Mirada Blvd, La Mirada, CA 90638 |
| Phone Number | 562-943-7156 |
News Archive
Gen-Probe announced today that Health Canada has granted the Company a medical device license for the PROGENSA(R) PCA3 assay, a new molecular urine test that helps determine the need for repeat biopsies in men suspected of having prostate cancer.
Boston Medical Center has been chosen to lead an investigation aimed at developing novel approaches to prevent tuberculosis. Jerrold J. Ellner, MD, chief of the section of infectious diseases at BMC and professor of medicine at the Boston University School of Medicine, a renowned expert in the field, will serve as principal investigator on the five-year, $3 million grant funded by the National Institutes of Health.
Osteotech, Inc. ( NASDAQ:OSTE ) , a leader in the emerging field of biologic solutions for regenerative medicine, announced today that the United States Patent and Trademark Office has confirmed the validity of its U.S. Patent No. 5,676,146.
Aperio Technologies, Inc., (Aperio), a global leader in digital pathology for the healthcare and life sciences industry, announced today that the United States Patent and Trademark Office has issued the company patent No. 7,457,446 entitled "Fully Automatic Rapid Microscope Slide Scanner."
The aldosterone antagonist eplerenone significantly reduced the development of new onset atrial fibrillation and flutter in patients with class 2 heart failure, concludes a sub-analysis of the EMPHASIS-HF trial, presented at the Heart Failure Congress 2011, organized by the Heart Failure Association of the European Society of Cardiology.
› Verified 5 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Gen-Probe announced today that Health Canada has granted the Company a medical device license for the PROGENSA(R) PCA3 assay, a new molecular urine test that helps determine the need for repeat biopsies in men suspected of having prostate cancer.
Boston Medical Center has been chosen to lead an investigation aimed at developing novel approaches to prevent tuberculosis. Jerrold J. Ellner, MD, chief of the section of infectious diseases at BMC and professor of medicine at the Boston University School of Medicine, a renowned expert in the field, will serve as principal investigator on the five-year, $3 million grant funded by the National Institutes of Health.
Osteotech, Inc. ( NASDAQ:OSTE ) , a leader in the emerging field of biologic solutions for regenerative medicine, announced today that the United States Patent and Trademark Office has confirmed the validity of its U.S. Patent No. 5,676,146.
Aperio Technologies, Inc., (Aperio), a global leader in digital pathology for the healthcare and life sciences industry, announced today that the United States Patent and Trademark Office has issued the company patent No. 7,457,446 entitled "Fully Automatic Rapid Microscope Slide Scanner."
The aldosterone antagonist eplerenone significantly reduced the development of new onset atrial fibrillation and flutter in patients with class 2 heart failure, concludes a sub-analysis of the EMPHASIS-HF trial, presented at the Heart Failure Congress 2011, organized by the Heart Failure Association of the European Society of Cardiology.
› Verified 5 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 3.38 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 6.6 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 25.89 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0.35 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 0.43 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 0 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 2.14 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 1.28 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 0 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 11.26 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 8.4 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 3.57 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 100 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 86.85 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 100 | 82.93 |
News Archive
Gen-Probe announced today that Health Canada has granted the Company a medical device license for the PROGENSA(R) PCA3 assay, a new molecular urine test that helps determine the need for repeat biopsies in men suspected of having prostate cancer.
Boston Medical Center has been chosen to lead an investigation aimed at developing novel approaches to prevent tuberculosis. Jerrold J. Ellner, MD, chief of the section of infectious diseases at BMC and professor of medicine at the Boston University School of Medicine, a renowned expert in the field, will serve as principal investigator on the five-year, $3 million grant funded by the National Institutes of Health.
Osteotech, Inc. ( NASDAQ:OSTE ) , a leader in the emerging field of biologic solutions for regenerative medicine, announced today that the United States Patent and Trademark Office has confirmed the validity of its U.S. Patent No. 5,676,146.
Aperio Technologies, Inc., (Aperio), a global leader in digital pathology for the healthcare and life sciences industry, announced today that the United States Patent and Trademark Office has issued the company patent No. 7,457,446 entitled "Fully Automatic Rapid Microscope Slide Scanner."
The aldosterone antagonist eplerenone significantly reduced the development of new onset atrial fibrillation and flutter in patients with class 2 heart failure, concludes a sub-analysis of the EMPHASIS-HF trial, presented at the Heart Failure Congress 2011, organized by the Heart Failure Association of the European Society of Cardiology.
› Verified 5 days ago
Mirada Hills Rehabilitation And Conv Hospital Location: 12200 La Mirada Blvd., La Mirada, California 90638 Phone: (562) 947-8691 | |
Imperial Healthcare Center Location: 11926 La Mirada Blvd, La Mirada, California 90638 Phone: (562) 943-7156 |